Torsade de pointes following intravenous haloperidol administration in a patient with complete heart block

Wisconsin Medical Journal

Volumn 108, Issue 1, 2009, Pages 48-50

  Ginwalla, Mahazarin ^a   Biblo, Lee Arnold ^a   Paydak, Hakan ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL;

AGED; AGITATION; ARTICLE; BRADYCARDIA; CASE REPORT; COMPLETE HEART BLOCK; DISEASE PREDISPOSITION; ELECTROCARDIOGRAM; HUMAN; MALE; MOOD DISORDER; PHYSICAL EXAMINATION; QT PROLONGATION; RISK FACTOR; TORSADE DES POINTES;

AGED; ANTIPSYCHOTIC AGENTS; ELECTROCARDIOGRAPHY; HALOPERIDOL; HEART BLOCK; HEART CATHETERIZATION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; TORSADES DE POINTES;

EID: 61449140961     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153:891-899.
2. O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. Ann Pharmacother. 1999;33:1046-1050.
3. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG. Anti-HERG activity and the risk of drug- induced arrhythmias and sudden death. Eur Heart J. 2005;26:590-597.
4. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463-469.
5. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm. 2005;2:S9-S15.
6. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM. Multiple mechanisms in the long-QT syndrome. current knowledge, gaps, and future directions. the SADS Foundation Task Force on LQTS. Circulation. 1996;94:1996-2012.
7. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82:282-290.
8. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363-1372.
9. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22:39-43.
10. Topilski I, Rogowski O, Rosso R, et al. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol. 2007;49:320-328.
11. Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use. Expert Opin Drug Saf. 2003;2:543-547.
12. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998;81:238-240.
13. Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf. 2005;28:35-51.